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RECURRENCE OF TYPE I MEMBRANOPROLIFERATIVE 
GLOMERULONEPHRITIS AFTER RENAL TRANSPLANTATION
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Background. The information in the medical litera­
ture on the incidence of recurrence of type I mem- 
branoproliferative glomerulonephritis (MPGN) after 
renal transplantation and its impact on graft survival 
is limited because most data are derived from case 
reports or from studies involving a small number of 
patients,
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Methods. We analyzed the data from our transplant 
center. Among 1097 adult patients receiving their first 
allograft between 1977 and 1994» we identified 32 pa­
tients with type I MPGN.
Results. A recurrence was detected in 9 of the 27
recipients of a first cadaveric graft (33%). The cumu­
lative incidence reached 48% at 4 years after trans­
plantation when patients with graft failure from other 
causes were censored. All patients with recurrent 
MPGN had clinically significant proteinuria (>1 g/24 
hr) that was first observed at a median time of 20 
months (range, 1.5-42 months) after transplantation. 
Graft survival was significantly worse in patients with
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recurrence as compared with patients without recur­
rence. Mean duration of graft survival after the diag­
nosis of recurrence was 40 months. We could not de- 
tect any clinical characteristics of patients or donors 
that were associated with recurrent disease. However, 
an increased risk of recurrence was observed in pa­
tients with the HLA haplotype B8DR3. Four patients 
received an HLA-identical graft from a living related 
donor. Recurrence occurred in three patients (75%), 
with ensuing graft loss in two. The only patient with a 
haploidentical living related graft did not have a re­
currence. Five patients with a recurrence in the first 
graft received a second transplant. Recurrence was 
observed in four of these patients (80%).
Conclusions. Type I MPGN recurred after renal 
transplantation in half of the patients. The incidence 
may be even higher in recipients of an identical living 
related donor graft and in patients receiving a second 
transplant after having experienced a recurrence in  
their first graft. Recurrence of type I MPGN has a 
detrimental effect on graft survival.
Type I membranoproliferative glomerulonephritis (MPGN,* 
alternatively named mesangiocapillary glomerulonephritis) is a 
rather uncommon form of glomerulonephritis. In most patients, 
the disease runs a progressive course toward end-stage renal 
failure, necessitating dialysis or kidney transplantation (I), 
Transplant recipients with type I MPGN can experience a re­
currence of the original disease in their allograft. The incidence 
of recurrence of type I MPGN has been reported to be as low as 
9% and as high as 53% (2,3). It is difficult to reconcile data in 
the literature, since most data are derived from case reports or 
from series involving a small number of patients.
We have studied the clinical course of 32 adult patients 
with type I MPGN who received a renal transplant in our 
center. In our study, we have specifically addressed the cu­
mulative incidence of recurrent type I MPGN among the 
recipients of cadaveric and living related donor grafts, the 
influence of recurrence on graft survival, and possible risk 
factors associated with recurrence.
PATIENTS AND METHODS
From all adult patients (age >14 years) who received transplants 
in the period between August 1977 and September 1994, we identi­
fied all known patients with type I MPGN. Whenever possible, the 
histology of the original renal biopsies was revised.
During the study period, the following immunosuppressive drug 
regimens were used: from 1977 to 1983 all patients were treated with 
prednisone (25 mg/day for 1 month, tapered to 10 mg/day after 4 
months) and azathioprine (3 mg/kg/day). From 1983 to 1985 patients 
were treated in a randomized study with either cyclosporine (CsA; 
starting with 17.5 mg/kg/day and tapering to 5 mg/kg/day a t 3 
months) and prednisone for the first 3 months followed by conversion 
to azathioprine and prednisone thereafter, or azathioprine and pred­
nisone for the whole period (4). From 1985 to 1989 all patients 
received CsA and prednisone during the first 3 months and azathio­
prine and prednisone thereafter. In the period from 1989 to 1992, 
patients were treated with CsA (starting with 12 mg/kg/day and 
tapering to 4 mg/kg/day at 3 months) and prednisone for the first 3 
months and thereafter randomized for continued treatment with 
either azathioprine and prednisone or CsA monotherapy (5). Since 
1992, the combination of CsA and prednisone has been the corner­
stone of the immunosuppressive therapy.
* Abbreviations: CsA, cyclosporine; MPGN, membranoprolifera­
tive glomerulonephritis.
All patients were followed after transplantation at regular inter­
vals (weekly for the first 4 months, every 2 -4  weeks thereafter, and 
from 1 year on at least every 3 months). At each visit, blood pressure, 
serum creatinine level, and urinary protein level were recorded. 
Throughout the study period, the criteria for performing a renal 
allograft biopsy were proteinuria (>2 g/24 hr) or a decrease in renal 
function.
For the purpose of this study, the medical records of all patients 
with type I MPGN were analyzed. The following data were docu­
mented for each patient: gender, age at diagnosis of the original 
disease (defined as the time of the first renal biopsy), time from 
diagnosis to end-stage renal failure, HLA tissue typing of donor and 
recipient, age at transplantation, donor source and gender, post­
transplant immunosuppressive therapy, occurrence of acute tubular 
necrosis, and occurrence of rejection episodes. Clinically significant 
proteinuria (> 1  g/day) heralded recurrence in all cases. Therefore, 
the date of onset of proteinuria was recorded and used as the date of 
onset of the recurrent disease.
The light microscopic changes of type I MPGN can be identical to 
those of chronic transplant glomerulopathy. Therefore, a definitive 
diagnosis of recurrent type I MPGN was made when the following 
biopsy criteria were fulfilled: (1 ) predominant deposition of C3 rather 
than IgM in the glomerular capillary wall on IF and (2) dense 
sub endothelial deposits on electron microscopy (5).
Statistical analyses, Dichotomous variables were analyzed by chi- 
square or Mantel-Haenszel test. For continuous parameters, com­
parisons were made with the unpaired Student’s t test (parametric) 
or the Mann-Whitney U  test (nonparametric variables). Survival 
probabilities were calculated with the Kaplan-Meier method, and the 
log-rank test was used for comparison of survival curves. A JP-value 
of <0.05 was considered to be statistically significant. Unless other­
wise noted, values are given as mean ± SD.
RESULTS
Among the 1097 adult patients receiving their first renal 
allograft, there were 463 patients w ith suspected glomerulo­
nephritis/glomerulopathy (42%). In 118 patients, glomerulo­
nephritis/glomerulopathy was secondary to systemic dis­
eases, such as amyloidosis, diabetes mellitus, or systemic 
lupus erythematosus. In  the 345 patients with a probable 
diagnosis of primary glomerulonephritis, a histological diag­
nosis was available in  61%. In  this group, we identified 32 
patients with type I MPGN as their original renal disease 
(15% of biopsy-proven cases of glomerulonephritis). The h is­
tological diagnosis of the original kidney disease could be 
revised and confirmed in 26 patients. No tissue from the 
native kidney was available for examination in the rem ain­
ing six patients, but the  available descriptions of the histol­
ogy and the clinical characteristics of the patients were com­
patible with the diagnosis of type I MPGN, The clinical 
characteristics of the 32 patients with type I MPGN are given 
in  Table 1. We analyzed the data according to donor source.
T able  1 . Clinical characteristics of patients with type I MPGN°
Sex (M/F) 22/10
Age at diagnosis (yr) 25±9
Interval diagnosis-ESRD (mo) 62±44
Age at transplantation (yr) 31±8
Donor source
Cadaver 27
LRD, identical 4
LRD, haploidentical 1
Abbreviations used in table: ESRD, end-stage renal disease; 
LRD, living related donor.
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Recipients o f cadaveric grafts . Twenty-seven patients 
were recipients of a first cadaveric graft. The average fol­
low-up was 59 months (range, 0.3-192 months). In the pa­
tients with graft loss, follow-up was term inated a t the time of 
graft failure. Six patients lost their grafts w ithin 9 months 
after transplantation. The follow-up of the remaining pa­
tients was a t least 12 months.
A recurrence was diagnosed in nine patients (33%); when 
patients with graft failure from other causes were censored, 
the cumulative incidence of recurrence reached 48% a t 4
100
years after transplantation (Fig. 1), Proteinuria of >  1 g/day 
was detected a t a median of 20 months after transplantation 
(range, 1.5-42 months; Fig. 1) and progressed to the ne­
phrotic range in all but one patien t (with the shortest fol­
low-up of only 1 year). In two patients with a  recurrence, 
deterioration of renal function coincided with the onset of 
proteinuria. In the rem aining seven patients, renal function 
was stable a t the onset of proteinuria. In  six of these patients, 
there was a significant and progressive increase of serum 
creatinine a t a median time of 16 months (range, 12-30 
months) after the onset of the clinical recurrence. Renal 
function rem ained stable in  only one patient, who died from 
septicemia a t 10 years after onset of proteinuria. Of the nine 
patients with recurrence, thus far seven have lost their kid­
neys, and the mean period of survival after the appearance of 
proteinuria was 40 months. Recurrence was the main cause 
of graft loss in five patients. One patient had a concomitant 
chronic vascular rejection and one patient died of septicemia 
with good renal function. At present, there are only two 
patients w ith functioning grafts; their serum creatinine lev­
els are 225 and 351 ¿tmol/L at 1 year and 4,5 years, respec­
tively, after transplantation.
To analyze the im pact of recurrent type I MPGN on graft 
survival, we compared graft survival of patients with recur­
rence and w ithout recurrence, thereby excluding the above- 
mentioned six patients with early graft loss. Graft survival 
was significantly worse in patients with recurrence (P<0.05,
Fig. 2).
For the analysis of risk  factors, we divided the patients 
into three groups: a group with proven recurrence, a group 
without recurrence (and a follow-up of >1 year), and a group
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with no evidence of recurrence but early graft loss (within 9 
months). Table 2 shows the characteristics of these patient 
groups. Sex, age at diagnosis, and the rate of progression of 
the original disease were not associated with the risk of 
recurrence. Also donor characteristics and the use of certain 
immunosuppressive regimens were not predictive. The only 
risk factor we identified was an HLA haplotype. The haplo- 
type HLA B8DR3 was associated with a higher risk of recur­
rence; 5 out of 9 patients with recurrence had this haplotype, 
compared with 1 out of 11 patients without recurrence 
(PC0.05).
In the study period, complement levels were not routinely 
measured after transplantation. From the medical records 
we obtained information on complement levels from seven 
patients with recurrence and from four patients without re­
currence. In these patients, a t least one measurement of C3 
was available before transplantation and one (>2 months) 
after transplantation. In the group with recurrence, four 
patients had a normal C3 before and after transplantation. 
Three patients had low C3 levels before transplantation, and 
these patients remained hypocomplementemic after trans­
plantation. On the other hand, the four patients without 
recurrence were hypocomplementemic before transplanta­
tion, and their C3 levels normalized within 2 months after 
transplantation.
Recipients o f grafts from living related donors. The risk of 
recurrence appeared higher in the patients who received an 
HLA-identical graft from a living donor, with recurrence in 
three of the four patients (75%). The onset of proteinuria was 
earlier than  in the recipients of cadaveric grafts, occurring at 
4, 6,5, and 12 months (Fig. 1), Two patients lost their grafts 
as a consequence of the recurrence at 4,5 and 5.5 years after 
transplantation. One patient has a functioning graft with a 
serum creatinine level of 116 ¡xmol/L at 1 year after trans­
plantation. None of the recipients of HLA-identical living 
related donor grafts had the HLA B8DR3 haplotype. The only 
patient with a haploidentical living related donor did not 
have a recurrence of type I MPGN.
Second transplantation, Five patients who lost their first 
graft due to recurrence received a second transplant. Recur­
rence occurred in four of them (80%) at 6, 12, 26, and 30 
months after transplantation (Fig. 1). Recurrence caused 
graft failure in three of these four patients, and the remain­
ing patient has deteriorating kidney function 3 years after 
transplantation. The only patient without a second recur-
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T able  2. Characteristics of patients with and without recurrent type I MPGN after first cadaveric transplantation®
With recurrence 
(n—9)
Early graft loss 
(n=6)
No recurrence 
(n—12) P
Sex (M/P) 4/5 3/3 10/2 NS
Age at diagnosis (yr) 28±9 21±6 24±10 NS
Interval diagnosis-ESRD (mo) 53±40 64±63 63±40 NS
Age at transplantation (yr) 35±10 27±5 32±8 NS
Donor age (yr) 34±13 36±18 37±15 NS
Donor sex (M/F) 6/3 2/4 4/8 NS
HLA mismatch 1.8 1.8 2.0 NS
HLA B8DR36 5 2 1 <0.05
ATN (n) 2 2 3 NS
Therapy after transplant
AZ A/prednisone 5 2 5 NS
CsA/prednisone 4 4 7 NS
Rejection (patients) 5 5 6 NS
No. of patients with graft failure 7 6 3
a Comparisons between groups were done with the Kruskall-Wallis or Mantel-Haenszel test when appropriate. Values are'given as mean ± 
SD. Abbreviations used in table: AZA, azathioprine; ESRD, end-stage renal disease; ATN, acute tubular necrosis.
6 The DR haplotype was unknown in one patient in the group without recurrence and in one patient in the group with an early graft loss.
T able  3, Overview of the literature on recurrent type I MPGN in renal transplants
Authors (Ref) No. of transplant recipients with type I MPGN
No. of patients 
with recurrence
Rate of recurrence
m 95% Cl*
Mathew et al. (27) 11 2 18 0.02-0.52
Berthoux et al. (14) 11 4 36 0.11-0.69
McLean et al. (15) 16 7 44 0.20-0.70
Hamburger et al. (28) 40 7 18 0.07-0.33
Curtis et al. (29) 4 1 25 0.01-0,81
Cameron et al. (2) 11 1 9 0.0-0.41
Morzycka et al. (19) 16 6 38 0.15-0.65
Moritz et al. (26) 8 1 13 0.0-0.53 .
O’Meara et al. (3) 15 8 53 0.27-0.79
Vangelista et al. (7) 15 4 27 0.08-0.65
Present study 32 12 38 0.21-0.56
Total 179 53 30 0.23-0.37
a Abbreviation used in table: Cl, confidence interval.
rence has retained good graft function 6 years after trans­
plantation.
Two of the patients without recurrence in the first graft 
(and graft survival >1 year) lost their grafts because of 
chronic vascular rejection. Both patients have received a 
second transplant, one a cadaveric graft and the other a 
haploidentical living related donor graft. Neither of these 
patients has evidence of recurrent disease in the second graft 
at 4 and 4.5 years after transplantation.
DISCUSSION
In our study, the overall incidence of recurrence of type I 
MPGN in patients who received a first renal allograft from a 
cadaveric donor was 33%. The incidence rate in previous 
studies has varied from a low of 9% to a high of 53%, with an 
average of 30% (Table 3). However, these overall percentages 
are likely to underestimate the actual recurrence rate, since 
the incidence of recurrence increases with time. In our study, 
the cumulative incidence of recurrent type I MPGN was as 
high as 48% at 4 years after transplantation. Our data sug­
gest that the widely referred to recurrence rate of 30% un­
derestimates the problem.
Could our results have been biased? We believe it is un­
likely that we have missed a large number of patients with
type I MPGN as original renal disease. In our center, a 
histological diagnosis was made in 61% of patients with 
suspected glomerulonephritis. This percentage compares fa­
vorably with the literature reporting 28—53% (3, 7). More­
over, most patients w ith type I MPGN present with clinically 
overt renal disease at a young age and are likely to undergo 
a biopsy. No tissue was available for revision in six patients, 
so we had to rely on the data  as reported in the medical 
records. Since none of these patients had a recurrence of 
MPGN, the inclusion of these patients may have biased our 
study toward underestim ation of the  recurrence rate. If we 
exclude these patients, the cumulative incidence of recur­
rence becomes as high as 71%.
The diagnosis of recurrence was based on characteristic 
findings on immunofluorescence and electron microscopy 
(£).3 Therefore, we consider it unlikely th a t we have overes­
timated the recurrence rate  in  our study.
Since we used strict biopsy criteria throughout the study, 
all patients w ith recurrent MPGN had clinical signs of recur­
rence, i.e., proteinuria with or w ithout renal function impair-
3 Assmann KJM, Andresdottir MB, Koene RAP, Wetzels JFM. 
Immunohistological and ultrastructural differences between recur­
rent membranoproliferative glomerulonephritis type I and chronic 
transplant glomerulopathy. Manuscript submitted for publication.
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ment. Clinically silent recurrences could certainly have been 
missed. However, in th ree patients without clinical recur­
rence, a biopsy was done a t 8, 10, and 30 months after 
transplantation because of im pairm ent of renal function. 
None of these patients showed evidence of histological recur­
rence .
The HLA B8DR3 haplotype was associated with an in­
creased risk of recurrence of type I MPGN. Admittedly, this 
finding is based on a small num ber of patients and is there­
fore suggestive bu t not conclusive. We are not aware of any 
reports on the association between certain alleles of the ma­
jor histocompatibility complex and recurrence of type I 
MPGN. Welch e t al. (8 ) have reported th a t patients with 
MPGN types I and III and the extended haplotype 
B8,DR3,SC01,GL02 more rapidly progress to end-stage re­
nal disease than  patients w ithout this haplotype. Our data do 
not allow us to draw firm conclusions on the  effect of the 
immunosuppressive regimen. Recurrence occurred both in 
patients treated  with azathioprine and prednisone and in 
patients treated with CsA and prednisone. However, most of 
our CsA-treated patients received CsA only in the first 3 -6  
months after transplantation. Only one study has suggested 
th a t the recurrence ra te  of type I MPGN was lower in CsA- 
treated patients (9). This finding, however, has not been 
confirmed by others (10, 11). Recent data  show an improved 
survival ra te  after transplantation  in patients with glomer­
ulonephritis since the introduction of CsA (12). It is unclear 
whether this improved survival is mediated in part by a 
lower rate of recurrence of glomerulonephritis.
For patients w ith type I MPGN in their native kidneys, it 
is known th a t the C3 component of complement and to a 
lesser extent C4 can be decreased in the course of the disease. 
However, C3 levels do not correlate with disease activity (I).
Berthoux (13) found th a t the persistence or recurrence of 
hypocomplementemia after transplantation was consistently 
followed by recurrence of the original disease. He also ob­
served th a t normal levels of complements were maintained 
by patients who were doing well (13). McLean et al. (14), on 
the other hand, did not find a clear correlation between 
hypocomplementemia after transplantation and recurrence. 
Our data on complement were limited and do not allow 
definite conclusions. They dem onstrate th a t persistently nor­
mal levels of C3 do not preclude the occurrence of recurrent 
disease. Furtherm ore, one m ight conclude th a t in patients 
with low C3 a t the time of transplantation, a persistently low 
C3 level favors a future recurrence, whereas patients with 
normalizing C3 levels have a favorable prognosis.
Recurrent type I MPGN had  a serious impact on allograft 
function. In five patients, graft loss was considered to be 
entirely caused by the recurrence.
In the literature, the ra te  of graft loss in patients with a 
recurrence of type I MPGN is reported to be about 30% (12, 
15-17). It is not always clear, however, w hether these data 
included only graft loss attributed entirely to the recurrence. 
In  our study, the  graft survival of patients w ith recurrence 
was poor and comparable to the outcome reported in other 
single-center studies. Morzycka et al. (18) observed graft loss 
in five of six patients with recurrence, O'Meara et al. (3) 
observed i t  in four of eight, Vangelista et al. (7) observed it in 
two of the four patients, and in  the series by Berthoux et al. 
(13) all four patients with recurrence lost the ir allograft.
The risk of recurrence was higher in patients who received 
a kidney from an identical living related donor (75%). How­
ever, the difference in the recurrence rate between recipients 
of cadaveric and identical living related donor grafts did not 
reach statistical significance, possibly due to the small num­
ber of patients. It is known that patients with IgA nephrop­
athy have a higher risk of recurrent disease when receiving a 
kidney from a living related donor (19-21). This information 
is not available for patients with type I MPGN, although two 
studies suggest tha t all forms of glomerulonephritis are more 
likely to occur in recipients of a living related donor graft (3, 
18).
We also observed a high risk of recurrence in a second graft 
in patients who had experienced a recurrence in the first 
graft (80%). To our knowledge, this is the first report of a 
series of patients who received a second transplantation after 
having lost their first graft due to recurrent type I MPGN, 
There have, however, been descriptions in the literature of 
several patients with a recurrence in two successive trans­
plants (13, 18, 22-25). These data strengthen our findings 
th a t patients with a recurrence in their first graft have a high 
risk of a second recurrence.
In summary, we found a high cumulative risk of recurrence 
of type I MPGN: 48% of patients with a first cadaveric graft 
a t 4 years after transplantation, 75% of the recipients of an 
identical living related graft, and 80% of recipients of a 
second cadaveric graft who had a recurrence in their first 
graft. The haplotype HLA B8DR3 may be associated with 
recurrence in patients with cadaveric grafts. Graft survival 
was negatively influenced by the recurrence.
REFERENCES
1. Glassock RJ, Cohen AH, Adler SG. Primary glomerular diseases. 
In: Brenner BM, ed. The Kidney, Philadelphia: Saunders, 1996: 
1392.
2. Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangio- 
capillary glomerulonephritis: comparison of types I and II in 
children and adults and long-term prognosis. Am J  Med 1983; 
74: 175.
3. O’Meara Y, Green A, Carmody M, et al. Recurrent glomerulone­
phritis in renal transplants: fourteen years’ experience. Nephrol 
Dial Transplant 1989; 4: 730.
4. Hoitsma AJ, Lier van HJJ, Wetzels JFM, Berden JHM, Koene 
RAP. Cyclosporin treatment with conversion after three months 
versus conventional immunosuppression in renal allograft recip­
ients. Lancet 1987; 14: 584.
5. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized, prospec­
tive trial of cyclosporine monotherapy versus azathioprine-pred- 
nisone from three months after renal transplantation. Trans­
plantation 1996; 61: 1038.
6. Cameron JS, Turner DR. Recurrent glomerulonephritis in al­
lografted kidneys. Clin Nephrol 1977; 7: 47.
7. Vangelista A, Frasca GM, Martella D, Bonomini V. Glomerulo­
nephritis in renal transplantation. Nephrol Dial Transplant 
1990; 5(suppl 1): 42.
8. Welch TR, Beischel L, Balakrishnan K, Quinlan M, West CD. 
Major-histocompatibility-complex extended haplotypes in mem­
bra noproliferative glomerulonephritis. N Engl J  Med 1986; 314: 
1476.
9. Tomlanovich S, Vincenti F, Amend W, et al. Is cyclosporine 
effective in preventing recurrence of immune-mediated glomer­
ular disease after renal transplantation? Transplant Proc 1988; 
20: 285.
10. Schwarz A, Krause P, Offerman G, Keller F. Recurrent and de
June 15, 1997 ANDRESDOTTIR ET AL. 1633
novo renal disease after kidney transplantation with or without 
cyclosporine A. Am J  Kidney Dis 1991; 17: 524,
1 1 . Freedman BI, Graves JW, Burkart JM, et al. The impact of 
different immunosuppressant regimens on recurrent glomerulo­
nephritis. Transplant Proc 1989; 2 1 : 2121.
12. Michielsen P. Recurrence of the original disease: does this influ­
ence renal graft failure? Kidney Int 1995; 48 (suppl 52): S79.
13. Berthoux FC, Ducret F, Colon S, Blanc-Brunat N, Zech PY, 
Traeger J. Renal transplantation in mesangioproliferative glo­
merulonephritis (MPGN): relationship between the high fre­
quency of recurrent glomerulonephritis and hypocomple­
mentemia. Kidney Int Suppl 1975; 7: S323.
14. McLean RH, Geiger H, Burke B, et al. Recurrence of membrano- 
proliferative glomerulonephritis following kidney transplanta­
tion. Am J  Med 1976; 60: 60.
15. Cameron JS. Glomerulonephritis in renal transplants. Trans­
plantation 1982; 34: 237.
16. Ramos EL. Recurrent diseases in the renal allograft. J  Am Soc 
Nephrol 1991; 2: 109.
17. Davison AM. Renal transplantation: recurrence of original dis­
ease with particular reference to primary glomerulonephritis. 
Nephrol Dial Transplant 1995; 10 (suppl 1 ): 81.
18. Morzycka M, Croker BP, Seigler HF, Tisher CC. Evaluation of 
recurrent glomerulonephritis in kidney allografts. Am J  Med 
1982; 72: 588.
19. Noël LH, Descamps B, Jüngers P, et al. HLA antigen in three 
types of glomerulonephritis. Clin Immunol Immunopathol 1978; 
10: 19.
20. Berger J, Noël LH, Nabarra B. Recurrence of mesangial IgA
nephropathy after renal transplantation. Contrib Nephrol 1984; 
40: 195.
21. Bachman U, Biava C, Amend W, et al. The clinical course of 
;A-nephropathy and He noch-Schönlein purpura following renal
transplantation. Transplantation 1986; 42: 511.
22. Glicklich D, Matas AJ, Sablay LB, et al. Recurrent membrano- 
proliferative glomerulonephritis type I in successive renal trans­
plants. Am J  Nephrol 1987; 7: 143.
23. Zimmerman SW, Hyman LR, Uehling DT, Burkholder PM. Re­
current membranoproliferative glomerulonephritis with glomer­
ular properdin deposition in allografts. Ann Intern Med 1974; 80: 
169.
24. Hamburger J, Berger J, Hinglais N, Descamps B. New insights 
into the pathogenesis of glomerulonephritis afforded by the 
study of renal allografts. Clin Nephrol 1973; 1 : 3.
25. Moritz MJ, Burke JF, Jarrell BE, Carabasi RA. The incidence of 
membranoproliferative glomerulonephritis in renal allografts. 
Transplant Proc 1987; 19: 2206.
26. Mathew TH, Mathews DC, Hobbs JB, Kincaid-Smith P. Glomer­
ular lesions after renal transplantation. Am J  Med 1975; 59:177.
27. Hamburger J, Crosnier J, Noel LH. Recurrent glomerulonephri­
tis after renal transplantation. Annu Rev Med 1978; 29: 67.
28. Curtis JJ, Wyatt RJ, Bhathena D, Lucas BA, Holland NH, Luke 
RG. Renal transplantation for patients with type I and type II 
membranoproliferative glomerulonephritis. Am J  Med 1979; 66: 
216.
Received 24 October 1996.
Accepted 5 February 1997.
